The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Roflumilast (Daxas®) has been rejected as an add on to bronchodilator treatment in severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in 1 second post-bronchodilator <50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations. The manufacturer did not present a sufficiently robust economic analysis.
Four combined oral contraceptive pills (Rigevidon®, Gedarel®, Millinette® and TriRegol®) were all accepted for use in patients where these products would provide an appropriate form of contraception. They provide an alternative to the existing preparations at a lower cost.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Update - October 2010||Bisphosphonates and fracture risk »|